CytoDyn Inc. (CYDY) Analysts See $-0.06 EPS

June 15, 2018 - By Catherine Nunes

CytoDyn Inc. (OTCMKTS:CYDY) Logo

Analysts expect CytoDyn Inc. (OTCMKTS:CYDY) to report $-0.06 EPS on July, 19. The stock decreased 1.61% or $0.01 during the last trading session, reaching $0.47. About 166,816 shares traded. CytoDyn Inc. (OTCMKTS:CYDY) has 0.00% since June 15, 2017 and is . It has underperformed by 12.57% the S&P500.

CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. The company has market cap of $101.86 million. The Company’s lead product under development for HIV infection include PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. It currently has negative earnings.

CytoDyn Inc. (OTCMKTS:CYDY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.